# Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

> clinical trial · VERIFIED · 2026-07-21

Status: SUSPENDED · Sponsor: National Cancer Institute (NCI) · Condition: Multiple Myeloma

- Company: National Cancer Institute (NCI)
- Sector: Multiple Myeloma
- Primary source: https://clinicaltrials.gov/study/NCT06876142

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.